scispace - formally typeset
G

Giancarlo Marenzi

Researcher at University of Milan

Publications -  204
Citations -  9769

Giancarlo Marenzi is an academic researcher from University of Milan. The author has contributed to research in topics: Myocardial infarction & Heart failure. The author has an hindex of 47, co-authored 180 publications receiving 8715 citations. Previous affiliations of Giancarlo Marenzi include University of California, Los Angeles.

Papers
More filters
Journal ArticleDOI

Circulating microRNAs are new and sensitive biomarkers of myocardial infarction

TL;DR: Acute MI up-regulated miR-1, - 133a, -133b, and -499-5p plasma levels, both in humans and mice, whereas miR -122 and -375 were lower than control only in STEMI patients and in mice with acute hind-limb ischaemia, there was no increase in the plasma level of the above miRNAs.
Journal ArticleDOI

Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction

TL;DR: Assessment of the incidence, clinical predictors, and outcome of contrast-induced nephropathy after primary percutaneous coronary intervention for acute myocardial infarction found that preventive strategies are needed, particularly in high-risk patients.
Journal ArticleDOI

N-Acetylcysteine and Contrast-Induced Nephropathy in Primary Angioplasty

TL;DR: Intravenous and oral N-acetylcysteine may prevent contrast-medium–induced nephropathy with a dose-dependent effect in patients treated with primary angioplasty and may improve hospital outcome.
Journal ArticleDOI

Improved clinical outcome after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial

TL;DR: Improved 1 year clinical outcomes in patients with acute myocardial infarction receiving intracoronary administration of bone marrow-derived progenitors cells (BMCs) after successful reperfusion therapy are shown.
Journal ArticleDOI

The Prevention of Radiocontrast-Agent–Induced Nephropathy by Hemofiltration

TL;DR: In patients with chronic renal failure who are undergoing percutaneous coronary interventions, periprocedural hemofiltration given in an ICU setting appears to be effective in preventing the deterioration of renal function due to contrast-agent-induced nephropathy and is associated with improved in-hospital and long-term outcomes.